Around 37% of GC tumors contain actionable somatic mutations (e.g. KRAS, TP53, PIK3CA) or gene amplifications (e.g. HER2, MET, EGFR, FGFR2, ERBB2) (64, 67–69). This evidence concerns the gene TP53 and gastric cancer.